EICHORCondition: Severe Hypertriglyceridemia · Sponsor: Zhejiang Doer Biologics Co., Ltd.
Interested? Contact the study team ↓
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus lifestyle management. Eligible participants complete a screening run-in period, then randomize equally to three treatment groups: two active DR10624 subcutaneous injection groups and one placebo group. All subjects maintain fixed oral background lipid therapy throughout long-term double-blind treatment, followed by a short safety follow-up period. The primary objective is to evaluate the triglyceride-lowering effect of DR10624 versus placebo. Secondary assessments include other lipid indicators, liver fat content, overall safety, and anti-drug antibody status. Independent committees monitor interim data and adjudicate key clinical events to ensure participant safety.
This description comes directly from the study's public registry record.
Yongliang Fang · +86 057128256206 · yf@dorebio.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Age ≥18 years, male or female; BMI 19.0-45.0 kg/m², body weight ≥50 kg at screening. 2. Fasting triglyceride (TG) range 5.65-22.60 mmol/L: single screening lab result meets range, plus average of two separate fasting TG tests (interval \>1 week) within same range prior to randomization. 3. Stable lipid-lowering medications per local guidelines if on statin, cholesterol absorption inhibitor or PCSK9 inhibitor (minimum stable dose duration as required by drug class). 4. Females of childbearing potential agree effective contraception from ICF signing to 2 months post last dose; male participants agree contraception and no sperm donation for 3 months post last dose. 5. Able to understand study procedures, maintain consistent lifestyle and follow all protocol-specified requirements, and provide written informed consent. Exclusion Criteria: 1. Confirmed hereditary lipid disorders (Fredrickson Type 1/3, Apo C-II deficiency). 2. Significant weight loss or planned weight reduction during study. 3. Severe chronic liver, renal or advanced cardiac disease. 4. Uncontrolled diabetes or hypertension with severe complications. 5. Pancreatitis history or symptomatic gallbladder disease. 6. Recent major cardiovascular, bone or thyroid disorders. 7. Severe psychiatric illness or substance abuse history. 8. Prior GLP-1/GCGR/FGF21 agonists or other investigational drugs within 3 months. 9. Abnormal screening lab parameters related to liver, pancreas, kidney or viral infection. 10. Pregnant, breastfeeding or hypersensitivity to study treatments. 11. Investigator's judgment of unsuitability for participation.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Peking University First Hospital | Beijing, China | — |
| Peking University People's Hospital | Beijing, China | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07680829